Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan vs Amlodipine on PPAR Gamma Activities in Hypertensive Metabolic Syndrome
NCT00242814Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of telmisartan in hypertension (HTN) and metabolic syndrome (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Serum adiponectin level at 6 weeks. Started Nov 2005; status: completed.
02
Drugs
telmisartan
03
Conditions
hypertension (HTN)metabolic syndrome
Beyond the preview
Go deeper on NCT00242814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242814.